In conclusion, fusion with the TXB4 module allows the TrkB agonist antibody to reach neuroprotective concentrations in the brain parenchyma following systemic administration, generating a new class of biologic with therapeutic potential in a wide range of neurodegenerative diseases, acute brain injury situations and possibly depression. The gene discussed is NTRK2; the disease is neurodegenerative disease.